The inventors have identified new peptide biomarkers related to methylglyoxal (MGO)- induced glycation of plasma albumin, as well as the most abundant plasma apolipoproteins. Plasma concentrations of MGH-APOB1003184-3194, MGH-ALB219-225, CEL-APOA229-39 were higher in patients with type 2 diabetes (T2D). After follow-up, cases of major adverse cardiovascular events (MACE), cases of severe coronary artery disease (CAD) events, cases of cardiovascular (CV) deaths and cases of all-cause deaths were reported in The SURDIAGENE study (n = 1425). Increased plasma concentrations of MGH-APOB1003184-3194, MGH-ALB219- 225, CEL-APOA229-39 were significantly associated with an increased risk of developing MACE, CAD, CV death, and/or CV death. Thus the present invention refers to a method of predicting the risk of having or developing a cardiovascular event in a patient.